Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 29 Recurrence 5 Hematologic Neoplasms 2 Waldenstrom Macroglobulinemia 1 Neoplasm, Residual 1 Myasthenia Gravis 1 Cytokine Release Syndrome 1

Interventions

Cyclophosphamide 12 fludarabine phosphate 7 fludarabine 7 venetoclax 6 blinatumomab 6 Cytarabine 5 Lenalidomide 4 Dexamethasone 4 Blood Specimen Collection 4 Azacitidine 4 obinutuzumab 3 Rituximab 3 Radiotherapy 3 Melphalan 3 Immunotherapy, Adoptive 3 pembrolizumab 2 daratumumab 2 Neoadjuvant Therapy 2 Idarubicin 2 Chemotherapy, Adjuvant 2 Capecitabine 2 trastuzumab deruxtecan 1 tislelizumab 1 tisagenlecleucel 1 thymoglobulin 1 tetrathiomolybdate 1 talquetamab 1 tagraxofusp 1 sacituzumab govitecan 1 sabatolimab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm, Residual × talquetamab × 1 year × Clear all

NCT06993675 2026-05-13

ROTATE

Yale University

Phase 2 Recruiting

Multiple Myeloma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡